Risk of Dementia in Older Breast Cancer Survivors: A Population-Based Cohort Study of the Association with Adjuvant Chemotherapy
Article first published online: 6 JAN 2009
© 2009, Copyright the Authors. Journal compilation © 2009, The American Geriatrics Society
Journal of the American Geriatrics Society
Volume 57, Issue 3, pages 403–411, March 2009
How to Cite
Baxter, N. N., Durham, S. B., Phillips, K.-A., Habermann, E. B. and Virning, B. A. (2009), Risk of Dementia in Older Breast Cancer Survivors: A Population-Based Cohort Study of the Association with Adjuvant Chemotherapy. Journal of the American Geriatrics Society, 57: 403–411. doi: 10.1111/j.1532-5415.2008.02130.x
- Issue published online: 3 MAR 2009
- Article first published online: 6 JAN 2009
- adjuvant chemotherapy;
- breast cancer;
- late effects
OBJECTIVES: To assess whether there is an association between delivery of adjuvant chemotherapy to older women with breast cancer and development of dementia over time.
DESIGN: Retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) data linked to Medicare claims data.
SETTING: Women residing in geographic areas included in the SEER registry.
PARTICIPANTS: Women aged 66 to 80 diagnosed with non-metastatic invasive breast cancer from 1992 to 1999 were included. It was determined whether patients had undergone chemotherapy within 6 months of diagnosis.
MEASUREMENTS: Whether women developed dementia over time was determined using diagnostic codes. The effect of adjuvant chemotherapy on development of dementia was evaluated, adjusting for confounders using a proportional hazards model stratified for age.
RESULTS: Twenty-one thousand three hundred sixty-two women met selection criteria; 2,913 received chemotherapy, and 18,449 did not. Women who received chemotherapy were younger than those who did not (median aged 70 vs 73; P<.001). Median follow-up time was 59 months. After controlling for other factors, it was found that chemotherapy was not associated with a greater risk of development of dementia over time for any age group (hazard ratio for dementia in women receiving chemotherapy: aged 66–70=0.83, 95% confidence interval (CI)=0.48–1.45, P=.5; aged 71–75=0.74, 95% CI=0.46–1.18, P=.2; aged 76–80=0.49, 95% CI=0.28–0.88, P=.02).
CONCLUSION: Receipt of chemotherapy in older women with breast cancer was not associated with a greater risk of dementia diagnosis over time; very elderly women who undergo chemotherapy may be at lower baseline risk. The use of a claims-based definition of dementia limited the study.